Table 1.
Study characteristics
| Author, year | Country | Study design | Group | No. of patients | Age(yr) | Gender(M/F) | BMI(kg/m2) | ASA (1:2:3) | Tumorsize (cm) | Tumor stage1 | Extent of LND | Population |
| Dulucq et al[28], 2005 | France | PCS | LTG | 8 | 75 ± 8 | 3/5 | NA | NA | 5.5 ± 2 | NA | D1 + β | EGC + AGC |
| OTG | 11 | 67 ± 14 | 5/6 | NA | NA | 6.1 ± 0.4 | NA | |||||
| Usui et al[9], 2005 | Japan | RCS | LTG | 20 | 66.0 ± 10.4 | 13/7 | 21.3 ± 3.1 | NA | NA | 8/10/2/0/0 | D1 + β | EGC + AGC |
| OTG | 19 | 66.2 ± 10.2 | 14/5 | 22.1 ± 2.4 | NA | NA | 10/8/1/0/0 | |||||
| Kim et al[34], 2008 | South Korea | RCS | LTG | 27 | 57.3 ± 14.2 | 16/11 | 22.6 ± 3.1 | NA | NA | NA | D1 + α/β, D2 | EGC + AGC |
| OTG | 33 | 61.6 ± 9.2 | 23/10 | 22.4 ± 2.1 | NA | NA | NA | |||||
| Mochiki et al[15], 2008 | Japan | RCS | LTG | 20 | 66 ± 2.4 | 16/4 | NA | NA | 3.6 ± 0.5 | NA | D1 + β | EGC |
| OTG | 18 | 63 ± 2.2 | 16/2 | NA | NA | 5.7 ± 0.8 | NA | |||||
| Topal et al[14], 2008 | Belgium | PCS | LTG | 38 | 68 (37-85) | 23/15 | 24 (17-30) | NA | 47 (7-180) | 0/17/7/10/4 | D2 | EGC + AGC |
| OTG | 22 | 69 (38-86) | 17/5 | 24 (17-30) | NA | 30 (10-180) | 0/7/7/6/2 | |||||
| Kawamura et al[30], 2009 | Japan | RCS | LTG | 46 | 64 ± 10.4 | 10/36 | 22.8 ± 3.0 | 15/27/4 | NA | NA | D2 | EGC |
| OTG | 35 | 65.2 ± 10.7 | 10/25 | 22.9 ± 2.4 | 14/15/6 | NA | NA | |||||
| Sakuramoto et al[16], 2009 | Japan | RCS | LTG | 30 | 63.7 ± 9.2 | 12/18 | 21.9 ± 2.7 | 9/20/1 | 4.0 ± 2.9 | 0/25/2/3/0 | D1 + β, D2 | EGC + AGC |
| OTG | 44 | 67.2 ± 9.9 | 10/34 | 22.5 ± 3.6 | 8/28/8 | 6.1 ± 3.7 | 0/15/17/12/0 | |||||
| Du et al[27], 2010 | China | RCS | LTG | 82 | 60.4 ± 18.5 | 54/28 | 22.3 ± 2.6 | NA | 5.4 ± 1.4 | 0/3/36/43/0 | D2 | AGC |
| OTG | 94 | 57.8 ± 17.2 | 61/33 | 22.5 ± 2.4 | NA | 5.9 ± 1.6 | 0/6/31/57/0 | |||||
| Kim et al[33], 2011 | South Korea | RCS | LTG | 63 | 55.9 ± 12.2 | 43/20 | 22.7 ± 2.5 | 45/15/3 | 3.8 ± 2.1 | NA | D2 | EGC |
| OTG | 127 | 57.3 ± 11.1 | 81/46 | 23.0 ± 2.9 | 86/39/2 | 3.9 ± 2.7 | NA | |||||
| Eom et al[10], 2012 | South Korea | RCS | LTG | 100 | 54.9 ± 13.5 | 57/43 | 22.7 ± 2.8 | NA | 4.3 ± 2.9 | NA | D1 + β, D2 | EGC + AGC |
| OTG | 348 | 58.7 ± 11.5 | 254/94 | 23.8 ± 2.9 | NA | 4.4 ± 3.0 | NA | |||||
| Guan et al[17], 2012 | China | RCS | LTG | 41 | 60.7 ± 9.1 | 33/8 | NA | NA | NA | 0/18/20/3/0 | D2 | EGC + AGC |
| OTG | 56 | 57.8 ± 9.9 | 40/16 | NA | NA | NA | 0/25/25/6/0 | |||||
| Siani et al[38], 2012 | Italy | RCS | LTG | 25 | 65 ± 8.5 | 15/10 | NA | NA | NA | 0/6/5/14/0 | D1 + α/β, D2 | EGC + AGC |
| OTG | 25 | 66 ± 7.8 | 18/7 | NA | NA | NA | 0/4/5/16/0 | |||||
| Kim et al[32], 2013 | South Korea | RCS | LTG | 139 | 58 (30-84) | 86/53 | 23.6 (13.6-32.4) | 85/46/8 | 3.2 (0.2, 15) | NA | D2 | EGC + AGC |
| OTG | 207 | 56 (31-84) | 134/73 | 24.1 (16.7-35.2) | 137/52/18 | 4.0 (0.3, 22) | NA | |||||
| Jeong et al[29], 2013 | South Korea | RCS | LTG | 122 | 63.2 ± 11.2 | 89/33 | 23.1 ± 3.4 | 33/80/9 | NA | NA | D1 + β, D2 | EGC + AGC |
| OTG | 122 | 62.6 ± 11.7 | 93/29 | 23.5 ± 3.2 | 43/67/12 | NA | NA | |||||
| Lee et al[37], 2013 | South Korea | RCS | LTG | 50 | 50.6 ± 22.1 | 32/18 | 23.2 ± 3.7 | 34/11/5 | NA | 0/24/13/9/4 | D2 | EGC + AGC |
| OTG | 50 | 51 ± 22.6 | 32/18 | 23 ± 3.4 | 31/16/3 | NA | 0/24/13/9/4 |
Continuous variables are presented as means ± SD or median and range.
1
Pathological tumor stage (0/I/II/III/IV). PCS: Prospective comparative study; RCS: Retrospective comparative study; LTG: Laparoscopic total gastrectomy; OTG: Open total gastrectomy; BMI: Body mass index; NA: Not available; ASA: American Society of Anesthesiologists; LND: Lymph node dissection; EGC: Early gastric cancer; AGC: Advanced gastric cancer; M/F: Male/female.